201286-65-9

Basic information

• Product Name: 4-BROMO-3,5-DIMETHYLPYRIDINE
• Synonyms: 4-BROMO-3,5-DIMETHYLPYRIDINE;4-Bromo-3,5-dimethylpyridine hydrochloride;4-Bromo-3,5-lutidine hydrochloride;4-Bromo-3,5-dimethylpyridine HCl
• CAS NO: 201286-65-9
• Molecular Formula: C₇H₈BrN
• Molecular Weight: 186.05
• Product Categories: Pyridine series;Building Blocks;Pyridine
• Mol File: 201286-65-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 235.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.415±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.81±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-3,5-DIMETHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3,5-DIMETHYLPYRIDINE(201286-65-9)
• EPA Substance Registry System: 4-BROMO-3,5-DIMETHYLPYRIDINE(201286-65-9)

Safety Data

• Hazardous Substances Data: 201286-65-9(Hazardous Substances Data)

Usage

Description

4-Bromo-3,5-dimethylpyridine is an organic compound characterized by the presence of a bromine atom at the 4-position and two methyl groups at the 3 and 5 positions on a pyridine ring. It is a versatile intermediate in the synthesis of various pharmaceuticals and organic compounds.

Uses

Used in Pharmaceutical Industry:
4-Bromo-3,5-dimethylpyridine is used as a key intermediate in the synthesis of Sulfonyl Indoles and related Bicyclic compounds. These compounds act as modulators of Liver X Receptor (LXR), which play a crucial role in regulating lipid metabolism, inflammation, and glucose homeostasis. By modulating LXR activity, these compounds can be employed for the treatment and prevention of LXR-mediated diseases, such as atherosclerosis, non-alcoholic steatohepatitis, and diabetes.

Upstream product

• 14248-66-9 3,5-dimethyl-4-nitropyridine-1-oxide 
• 7789-60-8 phosphorus tribromide 
• 70564-92-0 4-bromo-3,5-dimethyl-pyridine 1-oxide 
• 591-22-0 3,5-Lutidine 

Downstream Products

• 201286-64-8 3,5-dimethylpyridine-4-carbaldehyde 
• 1032358-13-6 4-(3,5-di-tert-butyl-4-methoxyphenyl)-3,5-dimethylpyridine 
• 1032358-02-3 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)-pyridine 

Relevant articles and documents

Halogen Bonding Molecular Capsules

Molecular capsules based solely on the interaction of halogen bonding (XB) are presented along with their host-guest binding properties in solution. The first example of a well-defined four-point XB supramolecular system is realized by decorating resorcin[4]arene cavitands with polarized halogen atoms for dimerization with tetra(4-pyridyl) resorcin[4]arene cavitands. NMR binding data for the F, Cl, Br, and I cavitands as the XB donor show association constants (Ka) of up to 5370 M-1 (ΔG283 K=-4.85 kcal mol-1, for I), even in XB-competitive solvent, such as deuterated benzene/acetone/methanol (70:30:1) at 283 K, where comparable monodentate model systems show no association. The XB capsular geometry is evidenced by two-dimensional HOESY NMR, and the thermodynamic profile shows that capsule formation is enthalpically driven. Either 1,4-dioxane or 1,4-dithiane are encapsulated within each of the two separate cavities within the XB capsule, with of up to Ka=9.0 108 M-2 (ΔG283 K=-11.6 kcal mol-1).

TETRACYCLIC INHIBITORS OF JANUS KINASES

The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

NOVEL SULFONYL DERIVATIVES

Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.